Platinum-doublet chemotherapy

DRUG4 trials

Sponsors

Regeneron Pharmaceuticals, Bristol-Myers Squibb, Xuanwu Hospital, Beijing

Conditions

Advanced MalignanciesAdvanced Non-small Cell Lung CancerAdvanced Solid TumorsResectable Non-Small-Cell Lung Cancer

Phase 1

Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies

Active, not recruitingNCT03233139

Regeneron PharmaceuticalsAdvanced Malignancies

Start: 2017-06-21End: 2027-09-30Updated: 2026-02-12

A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors

CompletedNCT05407675

Bristol-Myers SquibbAdvanced Solid Tumors

Start: 2022-08-02End: 2025-07-24Updated: 2025-10-03

Unknown Phase

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients

Active, not recruitingNCT06269133

Regeneron PharmaceuticalsAdvanced Non-small Cell Lung Cancer

Start: 2024-02-21End: 2027-06-23Target: 1000Updated: 2025-08-27

Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC

Not yet recruitingNCT06607926

Xuanwu Hospital, BeijingResectable Non-Small-Cell Lung Cancer

Start: 2024-10-15End: 2025-12-30Target: 40Updated: 2024-09-23

Related Papers

Evaluating the safety and effectiveness of cemiplimab in combination with platinum-doublet chemotherapy by demographic characteristics in first-line treatment of advanced non-small cell lung cancer: An ongoing multi-database real world evidence study in US patients.

Journal of Clinical Oncology2025-05-28

Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies.

2020-11-0411 citations